Cap-Dependent Endonuclease Inhibitors Research
This opportunity is closed
The response deadline has passed. Review the details for future reference or to track similar opportunities.
The Department of Defense is procuring cap-dependent endonuclease inhibitors (CENis) for the Naval Medical Research Command to support the development of broad-spectrum antiviral therapeutics. The project involves selecting lead candidates through in vitro and in vivo efficacy studies, requiring expertise in preclinical development with a focus on viruses that necessitate biosafety level 4 containment. The work is expected to be completed over a 36-month period.
Scope & Requirements
The project involves the preclinical development of CENis, focusing on selecting lead candidates and conducting efficacy studies.
Contract Details
- Estimated Value
- est. $120K – $1.2MSimilar contracts award $117K – $1.1M (median $350K, 72,549 awards)Within typical range
- Period of Performance
- 36 months
- NAICS Codes
- Place of Performance
- Fort Detrick, MD, USA
Agency & Contact
Contracting Organization
- Agency
- DEPT OF DEFENSE
- Sub-Agency
- NAVSUP FLC NORFOLK
Point of Contact
Key Dates
Description
The preclinical development of Cap-dependent endonuclease inhibitors (CENi), a class of small molecules, as broad-spectrum antiviral therapeutics. The scope of this project includes all activities required to select lead CENi candidates, including in vitro and in vivo efficacy studies and characterization and optimization of lead compounds. This includes Research Support expertise regarding the preclinical development of cap-dependent endonuclease inhibitors (CENis) with viruses that require biosafety level 4 (BSL-4) containment to support the Naval Medical Research Command in Fort Detrick, MD. This work will be performed over a 36-month period. Brian Kinkade Alternative
Point of Contact Jacob Gephart to this opportunity. Solicitation - N0018926QB059.pdf Combined Synopsis.pdf
Get matched to contracts like this daily
Free AI-powered contract matching for your business.